Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review

Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review

The purpose of androgen deprivation therapy (ADT) in prostate cancer (PCa), using luteinizing hormone-releasing hormone agonists (LHRHa) or gonadotrophin-releasing hormone antagonists, is to suppress the levels of testosterone. Since testosterone is the precursor of estradiol (E2), one of the major...

Full description

Bibliographic Details
Main Authors: Herjan J T Coelingh Bennink, Jan Krijgh, Jan F M Egberts, Maria Slootweg, Harm H E van Melick, Erik P M Roos, Diederik M Somford, Yvette Zimmerman, Iman J Schultz, Noel W Clarke, R Jeroen A van Moorselaar, Frans M J Debruyne
Format: Article
Language:English
Published: Bioscientifica 2022-11-01
Series:Endocrine Connections
Subjects:
androgen deprivation therapy (adt)
bone health
estrogen therapy (et)
transdermal estradiol (te2)
estetrol (e4)
Online Access:https://ec.bioscientifica.com/view/journals/ec/11/12/EC-22-0182.xml

Internet

https://ec.bioscientifica.com/view/journals/ec/11/12/EC-22-0182.xml

Similar Items